Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Guardant Health Inc’s stock clocked out at $94.13, down -3.79% from its previous closing price of $97.84. In other words, the price has decreased by -$3.79 from its previous closing price. On the day, 2.14 million shares were traded. GH stock price reached its highest trading level at $98.05 during the session, while it also had its lowest trading level at $93.51.
On April 10, 2025, Mizuho started tracking the stock assigning a Outperform rating and target price of $55.Mizuho initiated its Outperform rating on April 10, 2025, with a $55 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 07 ’25 when Hidalgo Medina Manuel sold 1,500 shares for $95.19 per share. The transaction valued at 142,780 led to the insider holds 815 shares of the business.
Saia John G. sold 8,996 shares of GH for $865,865 on Nov 07 ’25. The Chief Legal Officer now owns 43,172 shares after completing the transaction at $96.25 per share. On Nov 07 ’25, another insider, Hidalgo Medina Manuel, who serves as the Director of the company, bought 1,500 shares for $95.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 12225079296 and an Enterprise Value of 12610611200. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.49. Its current Enterprise Value per Revenue stands at 13.972 whereas that against EBITDA is -31.355.
Stock Price History:
The Beta on a monthly basis for GH is 1.60, which has changed by 2.3610444 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $101.57, while it has fallen to a 52-week low of $28.45. The 50-Day Moving Average of the stock is 34.35%, while the 200-Day Moving Average is calculated to be 78.31%.
Shares Statistics:
It appears that GH traded 2.69M shares on average per day over the past three months and 4453410 shares per day over the past ten days. A total of 125.01M shares are outstanding, with a floating share count of 123.69M. Insiders hold about 4.49% of the company’s shares, while institutions hold 94.98% stake in the company. Shares short for GH as of 1761868800 were 8415877 with a Short Ratio of 3.13, compared to 1759190400 on 8265188. Therefore, it implies a Short% of Shares Outstanding of 8415877 and a Short% of Float of 7.01.
Earnings Estimates
. The current market rating for Guardant Health Inc (GH) reflects the collective analysis of 15.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.29 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.73 and -$1.91 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$1.44, with 17.0 analysts recommending between -$0.89 and -$2.31.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $267.6M. It ranges from a high estimate of $270M to a low estimate of $264.6M. As of. The current estimate, Guardant Health Inc’s year-ago sales were $201.81MFor the next quarter, 19 analysts are estimating revenue of $271M. There is a high estimate of $284.1M for the next quarter, whereas the lowest estimate is $255.92M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $970.1M, while the lowest revenue estimate was $965.3M, resulting in an average revenue estimate of $968.42M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.32B and the low estimate is $1.16B.
